Trial Profile
Enhancing malignant melanoma immunological engagement using sequential therapy with ipilimumab and electrochemotherapy
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2020
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms EMMIE-IP
- 24 Apr 2020 Status changed from recruiting to discontinued.
- 07 May 2017 Planned number of patients changed from 30 to 10.
- 28 Apr 2016 New trial record